Teva Falls Short On Challenge To Velphoro Formulation Patent
Israeli Firm Has A Second Case Pending, Although A Trial Date Is Not Set
Teva has been shot down in its attempts to circumvent a key US patent shielding Vifor Pharma’s Velphoro dialysis drug.
You may also be interested in...
A proposed Teva Pharmaceutical generic would infringe on multiple patents for Tris Pharma’s QuilliChew ER, a New Jersey district court has ruled.
Teva’s Actavis looks unlikely to be launching its proposed generic version of Tris Pharma’s Quillivant XR (methylphenidate) extended-release oral suspension soon, after a remanded district court decision that went against the firm was upheld on appeal.
After over two years of litigation, Vifor and American Regent have reached agreements with Viatris’ Mylan and Sandoz regarding their generic ferric carboxymaltose products, allowing both companies to bring rivals to market ahead of the expiry of certain US patents.